• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[S-1、超选择性动脉内化疗与放射治疗联合治疗口腔癌的临床疗效]

[The clinical effect of combination therapy for oral cancer with S-1, superselective intra-arterial chemotherapy, and radiation therapy].

作者信息

Yamamoto Chika, Yoshikawa Hiromasa, Fukumoto Shunsuke, Higuchi Takashi, Yoshida Masanori, Horinouchi Yasufumi, Uehara Satoru, Yasumori Koutarou

机构信息

Dept. of Dentistry, Oral and Maxillofacial Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center.

出版信息

Gan To Kagaku Ryoho. 2011 Dec;38(13):2575-8.

PMID:22189221
Abstract

Combination therapy with S-1, superselective intra-arterial infusion of CBDCA and radiation therapy has been used to treat patients with oral cancer since 2005. In this study, the histopathological effects and toxicities following concurrent chemoradiotherapy were examined. The subjects consisted of 15 patients (10 men and 5 women) who were treated with S-1 (60-80 mg/day, 4 weeks), superselective intra-arterial infusion of CBDCA (300 mg/body) and radiation therapy (total dose 30-36 Gy) in our department from 2005 to 2009. Nine patients, showed T2 disease, 3 showed T3 disease, and another 3 showed T4 diseases. The primary cancer sites were the tongue (6 cases), buccal mucosa (4 cases), mandible gingival (3 cases), maxillary gingiva (1 case), and the floor of the mouth (1 case). The histopathological effects were evaluated according to Oboshi-Shimosato classification. Grade IV was shown in 10 cases (66. 7%), grade III in 1 case (6. 7%), II bin 3 cases (20. 0%), and II a in 1 case (6. 7%). All patients completed the treatment. The pathological response of the resected tumor was grade IIbor higher in 14 cases (93. 3%). While good histological effects were noted, there was one patient for whom viable tumor cells remained in the central part of the tumor. The present study indicates that further investigation is needed to determine the best dosing and dosing schedule.

摘要

自2005年以来,S-1、超选择性动脉内输注卡铂和放射治疗的联合疗法已被用于治疗口腔癌患者。在本研究中,对同步放化疗后的组织病理学效应和毒性进行了检查。研究对象包括15例患者(10例男性和5例女性),他们于2005年至2009年在我院接受了S-1治疗(60-80mg/天,共4周)、超选择性动脉内输注卡铂(300mg/人)和放射治疗(总剂量30-36Gy)。9例患者为T2期疾病,3例为T3期疾病,另外3例为T4期疾病。原发癌部位为舌(6例)、颊黏膜(4例)、下颌牙龈(3例)、上颌牙龈(1例)和口底(1例)。根据大星-下里分类法评估组织病理学效应。10例(66.7%)显示为IV级,1例(6.7%)为III级,3例(20.0%)为IIb级,1例(6.7%)为IIa级。所有患者均完成了治疗。切除肿瘤的病理反应在14例(93.3%)中为IIb级或更高。虽然观察到良好的组织学效应,但有1例患者肿瘤中央仍存在存活的肿瘤细胞。本研究表明,需要进一步研究以确定最佳剂量和给药方案。

相似文献

1
[The clinical effect of combination therapy for oral cancer with S-1, superselective intra-arterial chemotherapy, and radiation therapy].[S-1、超选择性动脉内化疗与放射治疗联合治疗口腔癌的临床疗效]
Gan To Kagaku Ryoho. 2011 Dec;38(13):2575-8.
2
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].[口服S-1后序贯多西他赛经超选择性动脉内灌注的联合化疗方案治疗口腔鳞状细胞癌患者的疗效评估]
Gan To Kagaku Ryoho. 2011 May;38(5):777-81.
3
Thermochemoradiation therapy using superselective intra-arterial infusion via superficial temporal and occipital arteries for oral cancer with N3 cervical lymph node metastases.采用超选择性经颞浅动脉和枕动脉动脉内灌注热化疗治疗伴有颈 N3 转移的口腔癌。
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e639-45. doi: 10.1016/j.ijrobp.2012.02.057. Epub 2012 Apr 28.
4
[Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].[S-1隔日口服疗法用于胃癌辅助化疗]
Gan To Kagaku Ryoho. 2012 Mar;39(3):385-7.
5
High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.新型口服氟嘧啶S-1治疗胰腺癌患者的缓解率较高。
Oncol Rep. 2002 Nov-Dec;9(6):1355-61.
6
Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.新型口服5-氟尿嘧啶联合低剂量顺铂作为口腔鳞状细胞癌术前化疗的II期研究。
Int J Clin Pharmacol Res. 2005;25(3):115-22.
7
Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.S-1单药治疗对紫杉醇和顺铂耐药的胃癌的II期研究。
Cancer Chemother Pharmacol. 2009 Dec;65(1):159-66. doi: 10.1007/s00280-009-1019-4. Epub 2009 May 29.
8
Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma.S-1同步放疗治疗口腔鳞状细胞癌的最佳方案研究
Oncol Rep. 2007 Nov;18(5):1077-83.
9
[Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer].奈达铂超选择性动脉内灌注联合放疗治疗晚期口腔癌的化疗临床试验
Gan To Kagaku Ryoho. 2005 Sep;32(9):1267-71.
10
[The feasibility of oral fluoropyrimidines as adjuvant chemotherapy after resection and local coagulation therapy of colorectal liver metastases].[口服氟嘧啶类药物作为结直肠癌肝转移切除及局部凝固治疗后辅助化疗的可行性]
Gan To Kagaku Ryoho. 2011 Nov;38(11):1821-4.